Published in final edited form as:

J Am Chem Soc. 2010 May 19; 132(19): 6663–6671. doi:10.1021/ja9082446.

Functional Characterization of TtnD and TtnF Unveiling New Insights into Tautomycetin Biosynthesis

Yinggang Luo^{†,Ω}, Wenli Li[†], Jianhua Ju[†], Qiuping Yuan[⊥], Noel R. Peters[⊥], F. Michael Hoffmann[⊥], Shengxiong Huang[†], Tim S. Bugni[†], Scott Rajske[†], Hiroyuki Osada[¥], and Ben Shen^{*,†,‡,§}

[†]Division of Pharmaceutical Sciences, University of Wisconsin, Madison, Wisconsin 53705-2222

[⊥]University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Small Molecule Screening Facility, University of Wisconsin, Madison, Wisconsin 53705-2222

[§]University of Wisconsin National Cooperative Drug Discovery Group, University of Wisconsin, Madison, Wisconsin 53705-2222

[‡]Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53705-2222

^ΩCenter for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China

[¥]Antibiotics Laboratory, Chemical Biology Department, Advanced Science Institute, RIKEN, Wako-shi, Saitama 351-0198, Japan

Abstract

The biosynthetic gene cluster for tautomycetin (TTN), a highly potent and selective protein phosphatase (PP) inhibitor isolated from *Streptomyces griseochromogenes*, has recently been cloned and sequenced. To better understand the transformations responsible for converting the post-polyketide synthase product into the exciting anticancer and immunosuppressive chemotherapeutic candidate TTN, we produced and characterized new analogues resulting from inactivation of two genes, *ttnD* and *ttnF*, in *S. griseochromogenes*. Inactivation of *ttnD* and *ttnF*, which encode for putative decarboxylase and dehydratase enzymes, respectively, afforded mutant strains SB13013 and SB13014. The $\Delta ttnD$ mutant SB13013 accumulated four new TTN analogues, TTN D-1, TTN D-2, TTN D-3, and TTN D-4 whereas the $\Delta ttnF$ mutant accumulated only one new TTN analogue, TTN F-1. The accumulation of these new TTN analogues defines the function of TtnD and TtnF and the timing of their chemistries in relation to installation of the C5 ketone moiety within TTN. Notably, all new analogues possess a structurally distinguishing carboxylic acid moiety, revealing that TtnD apparently cannot catalyze decarboxylation in the absence of TtnF. Additionally, cytotoxicity and PP inhibition assays reveal the importance of the functional groups installed by TtnDF and, consistent with earlier proposals, the C2"-C5 fragment of TTN to be a critical structural determinant behind the important and unique PP-1 selectivity displayed by TTN.

To whom correspondence should be addressed: Ben Shen, Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Ave., Madison, WI 53705-2222, USA. Tel: (608) 263-2673, Fax: (608) 262-5345, bshen@pharmacy.wisc.edu.

Supporting Information Available. Full experimental details describing production and confirmation of $\Delta ttnD$ and $\Delta ttnF$ mutant strains SB13013 and SB13014 and ¹H and ¹³C NMR spectra for new TTN analogues 3–7. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Introduction

Tautomycetin (TTN, **1**, Figure 1) and tautomycin (TTM, **2**) are potent cell permeable inhibitors of protein phosphatases (PPs) PP-1 and PP-2A and are recognized as potent inducers of apoptosis. TTN, first isolated from *Streptomyces griseochromogenes*,¹ displays nearly a 40-fold preference for PP-1 inhibition over PP2A and is the most selective PP1 inhibitor reported to date.² The PP-1 selectivity of **1** likely plays a role in the agent's extraordinary immunosuppressive activity³ and sharply contrasts the PP-2A selective inhibition by the natural product okadaic acid, another potent phosphatase inhibitor, making it a particularly useful tool.⁴ Indeed, **1** has been instrumental in dissecting the role of PP-1 in the MEK-ERK pathway.⁵ TTM, isolated from *Streptomyces spiroverticillatus* shares significant structural features with TTN yet displays only a weak preference for PP1 inhibition relative to PP2A².

We recently cloned and sequenced the biosynthetic gene clusters for both **1** and **2**.^{6,7} In the case of the highly selective PP-1 inhibitor **1**, the *ttn* biosynthetic gene cluster from *S. griseochromogenes* was characterized, and its involvement in **1** biosynthesis confirmed by gene inactivation and complementation experiments.⁶ The *ttn* cluster was localized to a 79-kb DNA region, consisting of nineteen open reading frames that encode two modular type I polyketide synthases (TtnAB), one type II thioesterase (TtnH), eight proteins for dialkylmaleic anhydride biosynthesis (TtnKLMNOPRS), four tailoring enzymes (TtnCDFI), two regulatory proteins (TtnGQ), and one resistance protein (TtnJ). On the basis of functional assignments for each gene in the *ttn* cluster obtained from sequence analysis we have formulated a model for biosynthesis of **1** that agrees well with previous feeding experiments, has been supported by *in vivo* gene inactivation experiments, and is supported by analogy to the recently reported *ttn* cluster. These findings set the stage to fully interrogate biosynthesis of **1**. Of particular interest is the means by which the C2"-C5 component (right hemisphere) is installed (Figure 1). This component of **1** differs significantly from the corresponding right hemisphere of **2** and has been proposed as a crucial determinant dictating the greater PP-1 selectivity of **1** relative to **2**.⁸⁻¹¹ This postulate has been substantiated by the recent crystal structure elucidation of PP-1 bound to **2** although high resolution structural information relating to PP-1 inhibition by **1** remains elusive.¹² Both **1** and **2** exist as equilibrating mixtures of anhydride and ring opened diacids^{1b,13,14}; the PP-1-to-**2** crystal structure reveals that the diacid form of **2** is the active PP-1 inhibitor and implies, by analogy, that the diacid form of anhydride **1** is the species directly responsible for PP-1 inhibition.¹²

Here, we report that inactivation of two genes, *ttnD* and *ttnF*, in *S. griseochromogenes* abolishes production of **1**, instead leading to five new analogues, TTN F-1 (**3**), TTN D-1 (**4**), TTN D-2 (**5**), TTN D-3 (**6**), and TTN D-4 (**7**), all of which lack the terminal C1"-C2" olefin, a critical feature of the right hemisphere of **1** (Figure 2). These findings support the proposed functions of TtnF and TtnD as a dehydratase and decarboxylase, respectively.⁶ Evaluation of the cytotoxicity and PP inhibitory activities of the new analogues highlight the importance of the C2"-C5 component in providing **1** with its ability to potently inhibit PP-1 in a highly selective fashion. These data significantly improve our understanding of TTN biosynthesis and PP inhibition by TTN.

Results

Construction and Evaluation of the $\Delta ttnD$ and $\Delta ttnF$ Mutant Strains SB13013 and SB13014

To confirm the proposed function of TtnD and TtnF, *in vivo* gene inactivations were performed by using REDIRECT Technology (Table S1, Supporting Information) as described previously.⁶ The mutant cosmids were introduced into *S. griseochromogenes* by conjugation, and the resultant double crossover mutants were confirmed by PCR and Southern blot analysis (Table S2, Supporting Information). Genetic complementations to the mutant strains were

subsequently carried out to eliminate the possibility of polar effects (Table S3, Supporting Information).

Isolation and Characterization of TTN Analogue 3 from SB13014 and TTN Analogues 4–7 from SB13013

Mutant strains SB13013 ($\Delta ttnD$) and SB13014 ($\Delta ttnF$) were fermented according to TTN production methods previously reported for the *S. griseochromogenes* wild-type strain, and corresponding metabolites were analyzed by HPLC with authentic TTN as a control.⁶ Only one TTN analogue **3** was accumulated and isolated from the $\Delta ttnF$ mutant strain SB13014 (Figure 2). Its molecular formula $C_{34}H_{54}O_{12}$ was established from the quasi-molecular ion at m/z 653.3532 ($[M-H]^-$), requiring an additional CH_4O_2 moiety relative to **1**. Instead of the C2"-C5 moiety present in the right fragment of **1**, only one trisubstituted olefin was deduced in **3** based on characteristic NMR signals at δ_H 5.48 (1H, t, $J=7.0$), δ_C 127.1 (d) and 141.4 (s) (Table 1). Two substituted groups, one β -hydroxypropanoic acid moiety (C1"-C3") and one ethyl moiety (C1-C2), were observed in the 1-D and 2-D NMR data with connectivity to the carbon observed at 141.4 ppm (s, C-3) of the only double bond (Table 1). The third substituent of this double bond was assigned as a methylene group in view of the characteristic 1H NMR triplet signal observed at δ_H 5.48 (1H, t, $J=7.0$). This assignment was confirmed by HMQC and HMBC signals (Figure 3A). Thus, the C5 of **3** was assigned as a methylene group and not a ketone. The upfield NMR signals were consistent with those previously observed for **1** and were assigned on the basis of 2-D NMR cross signals (Table 1 and Figure 3A). The stereochemical configurations at C7, C9, C12, C13, C16, C17, C18, and C3' are suggested to be identical to those of **1** on the basis of their shared biosynthetic origin and the very similar optical rotations observed for **1** and **3**. Although we could predict a *R*-configuration for C1" of **3** on the basis of bioinformatics comparisons of conserved amino acid residues of the TTN polyketide synthase KR domain and those of KR domains associated with stereochemically defined natural products,¹⁵ the absolute stereochemistry was not established experimentally. Attempts to make the Mosher ester of **3** were unsuccessful, with **3** undergoing rapid dehydration to **4** under all conditions examined.¹⁶

Four TTN analogues **4**, **5**, **6**, and **7** were accumulated and isolated from the $\Delta ttnD$ mutant strain SB13013 (Figure 2). Their structures were elucidated on the basis of 1-D and 2-D NMR (including 1H - and ^{13}C -NMR, 1H - 1H COSY, HMQC, and HMBC data), UV, IR, and HRMS data. The molecular formula of **4**, $C_{34}H_{52}O_{11}$, was established from the quasi-molecular ion at m/z 659.3412 ($[M+Na]^+$), requiring one H_2O less than **3**. The only difference between **4** and **3** was that **4** is not a β -hydroxypropanoic acid moiety, but rather, an acrylic acid moiety attached to C3 as deduced from its 1-D and 2-D NMR data (Table 1). The characteristic coupling constant 15.2 Hz between the two protons at δ_H 7.28 and 5.78 (each 1H, d, $J=15.2$) suggests a *trans*-double bond within the acrylic acid moiety (Table 1). The upfield NMR signals were consistent with those of **3** and were assigned by 2-D NMR cross signals (Table 1 and Figure 3A). Stereochemical configurations at C7, C9, C12, C13, C16, C17, C18, and C3' are predicted to be identical to those of **1** based on the shared biosynthetic origin of **1** and **4**.

The molecular formula $C_{34}H_{52}O_{12}$ of **5** was established from the quasi-molecular ion at m/z 651.3400 ($[M-H]^-$), requiring one more oxygen atom than **4**. The only difference between **5** and **4** was that the characteristic 1H NMR signal of the proton of C4 is a doublet at δ_H 5.77 (1H, d, $J=8.8$), instead of the triplet signal observed in **3** and **4**. Thus, C5 was assigned as a methine group instead of a methylene moiety, which is the case for **3** and **4**. In view of the NMR signals at δ_H 4.58 (1H, q-like, $J=7.6$) and δ_C 66.6 (d), the oxygenation at C5 was deduced. C5 oxygenation was confirmed by 1H - 1H COSY, HMQC, and HMBC cross signals (Table 2 and Figure 3A). The upfield NMR signals were consistent with those of **4** and were assigned by 2-D NMR cross signals (Table 2 and Figure 3A). Stereochemical configurations spanning

C3' to C7 (with the exception of C5) were assigned in a fashion analogous to that used for compounds **3** and **4**.

The molecular formula of $C_{34}H_{52}O_{12}$ of **6**, deduced on the basis of the quasi-molecular ion at m/z 651.3399 ($[M-H]^-$), is identical to that of **5**. The NMR spectra of **5** and **6** were almost superimposable (Table 2 and Figure 3A). The only discernible difference between the two compounds was their 1H and ^{13}C NMR signals around C5, suggestive of a diastereomeric relationship between **5** and **6**, the result of opposite configurations at C5. The exact configuration at C5 for **5** was subsequently assigned on the basis of extensive HETLOC, gHSQMBC, and gDQCOSY experiments.^{17,18} Thus, the anti-orientations of H^b -6/ H -5 was suggested by the observed large 3J value (9.0 Hz), while the gauche orientations of H^l -6/ H -5, H^l -6/ H -7, and H^b -6/ H -7 were supported by the small 3J values. The anti-orientations of H^l -6/OH and H^l -6/7-Me were shown by the small 2J value for H^l -6/C5 and the large 3J value (6.0 Hz) for H^l -6/7-Me, respectively. The gauche orientation of H^b -6/5-OH was suggested by the large 2J value (6.8 Hz) (Figure 3B). Taken together, an *S*-configuration was assigned to C5 of **5**, thereby a *R*-configuration at C5 for **6** on the basis of their a diastereomeric relationship (Table 2 and Figure 2B).

For **7**, a molecular formula of $C_{34}H_{50}O_{12}$ was established from the quasi-molecular ion at m/z 649.3219 ($[M-H]^-$), requiring two protons less than **5**. The only difference between **7** and **5** was that the characteristic 1H resonance for the C4 proton in **7** was a singlet at δ_H 6.34 (1H, s), instead of a triplet as observed for **3** and **4**, or a doublet as observed for **5** and **6**. The suggestion, on the basis of these data, that C5 of **7** was a carbonyl carbon was prompted by the observed ^{13}C NMR signal at δ_C 201.5 (s) indicative of a quaternary carbon. The identity of C5 in **7** as a ketone carbon was confirmed by HMBC cross signals (Table 1 and Figure 3A) and is the only significant structural difference between **7** and its putative methylene precursor compound **4** (Figure 2B). The upfield NMR signals for **7** were consistent with those of **1** and its analogues and were assigned by 2-D NMR cross signals (Table 1 and Figure 3A). Stereochemical configurations at C7, C9, C12, C13, C16, C17, C18, and C3' in **7** are likely identical to those observed in **1** on the basis of the compounds' shared biosynthetic origin.

Evaluation of PP Inhibitory Activity and Cytotoxicity of 3–7 in Comparison with 1

Compounds **3–7** were subjected to PP inhibition and cytotoxicity assays with **1** as a control.¹⁹ Assays focused specifically on the inhibition of PP-1 and PP-2A (Table 3), while cytotoxicity assays exploited the use of selected human cancer cell lines Du145, MCF7, and HCT-115 (Table 4).

Discussion

The C2"-C5 fragment of **1** is not consistent with structural expectations for the nascent polyketide resulting from the TtnAB polyketide synthase as predicted previously.⁶ The involvement of post-polyketide synthase steps en route to **1** was supported by the presence of four genes associated with putative tailoring enzymes: TtnC, a flavoprotein decarboxylase homolog; TtnD, a UbiD family decarboxylase homolog; TtnF, an L-carnitine dehydratase homolog; and TtnI, a putative cytochrome P450.⁶ On the basis of these functional assignments and the predicted synthetic capabilities of the TtnAB polyketide synthases, we have proposed previously **1** to arise through the intermediacy of a β -hydroxy acid intermediate (Figure 4).⁶ Concomitant decarboxylation and dehydration to form the terminal olefin has been previously suggested,^{17,18} and olefin installation in this manner was postulated to benefit substantially from the presence of the C5 ketone and its conjugation with the C3-C4 olefin.

The true functions of putative dehydratase TtnF and decarboxylase TtnD were evaluated using gene inactivation strategies followed by examining metabolite profiles of the resultant mutant

strains. It is significant to note that under no circumstances was the previously postulated β -hydroxy acid intermediate observed, and this finding is consistent with the alternative idea that C5 oxidation proceeds after the chemistries of TtnD and TtnF (Figure 4). The $\Delta ttnF$ mutant SB13014 accumulated **3** whereas the $\Delta ttnD$ mutant SB13013 accumulated compounds **4–7**. The accumulation of **3** in the $\Delta ttnF$ mutant reveals three important details about the biosynthesis of **1** (Figure 2). First, it confirms the functional assignment of TtnF as a dehydratase. Second, and perhaps more surprising, is that retention of the terminal acid in **3** suggests that the decarboxylase activity of TtnD requires the presence of TtnF; TtnD alone is not sufficient to effect decarboxylation. Conventional reactivity considerations dictate that dehydration of the allylic C1" in **3** or related compounds might occur upon TtnD-catalyzed decarboxylation. However, the accumulation of **3** in the presence of TtnD but the absence of TtnF reveals the flaw in this thinking as does the fact that no trace of **1**, **4**, **5**, **6**, or **7** could be found in fermentations of the $\Delta ttnF$ mutant SB13014. The biosynthetic transformations catalyzed by TtnD and TtnF appear to occur in concert. Conversely, TtnF-catalyzed dehydration of C1" is in no way dependent upon the decarboxylase activity of TtnD as reflected by the absence of the C1" OH moiety in all compounds accumulated by the $\Delta ttnD$ mutant SB13013. Third, the accumulation of **3** by $\Delta ttnF$ mutant SB13014 reveals that dehydration chemistry precedes polyketide C-5 oxidation needed for ketone installation. This is not the case for the $\Delta ttnD$ mutant SB13013, which accumulated the C5 ketone **7** in addition to compounds **4–6**. TtnI, a cytochrome P450 homolog, the only oxygenase within the *ttn* cluster and a putative C5 oxidase, is likely responsible for conversion of **4** into **7**. That **4–6**, and not just **7**, accumulate in SB13013 suggests that the $\Delta ttnD$ mutant accumulates impaired TtnI substrates. It is clear that the activities of TtnD, TtnF and TtnI are, to varying extents, impacted by the chemistries catalyzed by each other.

The accumulation of **3** by the $\Delta ttnF$ mutant SB13014 and **4–7** by the $\Delta ttnD$ mutant SB13013 allows us to more accurately predict the biosynthesis of **1** (Figure 4). Previous inactivation experiments indicate that TTN biosynthesis proceeds by a linear pathway.⁶ The dialkylmaleic anhydride unit is coupled to the growing TTN polyketide intermediate prior to its release from the polyketide synthase with the dialkylmaleic anhydride being constructed *via* an independent pathway that relies on TtnLMNOPRS.⁶ Hence, we envision a biosynthetic pathway in which acetyl CoA, malonyl CoA, methylmalonyl CoA and ethylmalonyl CoA are used by the two polyketide synthases TtnAB to produce, after TtnK-mediated dialkylmaleic anhydride coupling, **3** (Figure 4). The absence of any C5 oxygenated analogues of **3** accumulated by the $\Delta ttnF$ mutant SB13014 suggests that TtnF-catalyzed chemistry precedes that of TtnI, an observation leading us now to postulate that, once formed, **3** is dehydrated by TtnF to provide diene **4**.⁶ The findings would also be consistent with an alternative scenario wherein TtnF and TtnD act in concert to produce a diene intermediate, a substrate then for C5 oxidation by TtnI (Figure 4). Both biosynthetic hypotheses for ultimate conversion of **3** to **1** relegate C5 oxidation to a late stage transformation although further inactivation efforts are warranted to determine the precise timing and coordination of the steps catalyzed by TtnF, TtnI, and TtnD. Finally, the accumulation of C5 alcohols **5** and **6** in the $\Delta ttnD$ mutant SB13013 could have resulted from C5 oxidation of compound **4** or C5 reduction of compound **7** by adventitious enzymes. However, regardless of the precise means by which **5** and **6** are produced, that both stereoisomers at C5 are observed correlates well with the production of **5** and **6** as shunt metabolites rather than intermediates formed by the stereospecific biosynthetic machinery driving production of **1**.

A critical distinction between **1** and **2** is the significantly greater selectivity of **1** for inhibition of PP-1 over PP-2A relative to **2**.^{8–11} Yet surprisingly, little attention has been directed to the generation of TTN analogues able to shed insight into the structural basis for this selectivity; **3–7** are among the first TTN analogues reported. In light of extensive efforts to produce analogues of **2** as possible drug candidates, the lack of interest in analogue generation with **1**

is truly remarkable.^{8–11,23–26} To investigate the impact of right hemisphere modification upon TTN bioactivity **1**, **3–7** were subjected to PP inhibition and cytotoxicity assays as previously described.⁶ Assays focused specifically on the inhibition of PP-1 and PP-2A, while cytotoxicity assays exploited the use of selected human cancer cell lines Du145, MCF7, and HCT-115.¹⁹ Thus, as summarized in Table 4, the impact of right hemisphere modifications on cytotoxicity appeared mixed. While the new analogues **3**, **4**, and **5** were inactive, **6** and **7** retained significant, albeit reduced, cytotoxicity (within 3-folds of reduction relative to **1**). In contrast, modifications of the right hemisphere of **1** clearly had a profound, uniform impact on its PP-1 selectivity. As shown in Table 3, **1** potently inhibited both PP-1 and PP-2 and did so with a PP-1 selectivity of about 27-fold. Analogues **3**, **4**, **6**, and **7** inhibited PP-1 less efficiently than **1** by approximately one order of magnitude yet inhibited PP-2A with about the same potency as **1**. In effect, any change to the C2"-C5 portion of **1** led to a significant decrease in PP-1 selective inhibition, a key trademark of **1**. Not only was this the case for **3**, **4**, **6**, and **7** but this was observed also for **5**, which was a significantly poorer PP inhibitor than any other right hemisphere congener tested. PP-1 inhibition by **5** was approximately three orders of magnitude worse than for **1**, and PP-2A inhibition by **5** was about two orders of magnitude worse than for **1**. Hence, although the PP-1 selectivity of **5** is on par with all other analogues tested, the absolute inhibitory activity of **5** was markedly less than for all other analogues, even its diastereomer **6**. The precise molecular origins of the more dramatically altered activity of **5** relative to other TTN analogues are uncertain. However, the results of these studies support proposals implicating the right hemisphere of **1** as providing much of the compound's PP-1 selectivity relative to PP-2A.^{8–11}

Taken together, our ability to correlate inactivation of the *ttnD* and *ttnF* genes with specific structural modifications to **1** supports the significance of the genetic system developed for the TTN producer *S. griseochromogenes* during sequencing of the *ttn* biosynthetic gene cluster and reinforces current functional assignments for all genes in the *ttn* cluster. The accumulation of compounds **3–7** in $\Delta ttnD$ and $\Delta ttnF$ mutant strains SB13013 and SB13014 sheds significant new insight into how the C2"-C5 fragment of **1** is produced and how these chemistries might be applied in a combinatorial biosynthetic fashion to produce new analogues of **1**. Production of **3–7** has also allowed us to critically evaluate some of the structural determinants responsible for the PP-1 selectivity of **1** relative to other PP inhibitors and general cytotoxicities against selected human cancer cells. These data establish an excellent stage for future investigations of TTN biosynthesis and the future generation of TTN analogues by manipulating the **1** biosynthetic machinery.

Experimental Procedures

General

IR spectra were measured on a Bruker EQUINOX 55/S FT-IR/NIR spectrophotometer (Ettlingen, DE). Optical rotations were determined on a Perkin-Elmer 241 instrument at the sodium D line (589 nm). High resolution mass spectrum (HRMS) analyses were acquired on an IonSpec HiResMALDI FT-Mass spectrometer (Lake Forest, CA) for HRMALDIMS or on an Agilent 1100 series LC/MSD Trap SL for HRESIMS (Santa Clara, CA). NMR data were recorded on a Varian Unity Inova 400 or 500 MHz NMR Spectrometer (Varian, Inc., Palo Alto, CA). ¹H- and ¹³C-NMR chemical shifts were referenced to residual solvent signals: δ_H 7.26 ppm and δ_C 77.7 ppm for CDCl₃. ¹H-¹H COSY, HMQC, HMBC, HETLOC, gHSQMBC, and gDQCOSY were performed using either standard VARIAN pulse sequences or literature pulse sequences.^{17,18} High performance liquid chromatography (HPLC) analysis was carried out a Varian HPLC system equipped with ProStar 210 pumps and a photodiode detector. Mobile phases used were buffer A (H₂O) and buffer B (CH₃CN). Analytical and semi-preparative HPLC columns used were Alltech Alltima C18 column 250 × 4.6 mm, 5 μ m and

250 × 10 mm, 5 μm, respectively. Cytotoxicity assays and PP inhibition assays for TTN and related analogues were performed as previously described for compound **2** and related congeners.¹⁹ Medium components and all other chemical solvents and reagents were commercially from Fisher Scientific (Fairlawn, NJ). Silica gel 60 RP-18 (230–400 mesh, EMD Chemical Inc., Gibbstown, NJ) was used for standard bench-top column chromatography. Amberlite XAD-16 resin was purchased from Sigma.

Bacterial Strains and Plasmids

Escherichia coli DH5α was used as the host for general subcloning.²⁷ *E. coli* ET12567/pUZ8002²⁸ was used as the cosmid donor host for *E. coli-Streptomyces* conjugation. *E. coli* BW25113/pIJ790 and *E. coli* DH5α/pIJ773 were provided by John Innes Center (Norwich, UK) as a part of the REDIRECT Technology kit.²⁹ The *S. griseochromogenes* wild-type strain has been described previously.^{1b,14}

Biochemicals, Chemicals, and Media

Common biochemicals and chemicals were from standard commercial sources. *E. coli* strains carrying plasmids were grown in Luria-Bertani (LB) medium with appropriate antibiotics selection.²⁷ All media for *Streptomyces* growth were prepared according to standard protocols.³⁰ ISP-4 and tryptic soy broth (TSB) were from Difco Laboratories (Detroit, MI), and modified ISP-4 is ISP-4 supplemented with 0.05% yeast extract and 0.1% tryptone.³¹ ISP-4 medium and MS medium were used for *S. griseochromogenes* sporulation at 30°C for 5–7 days.

S. griseochromogenes Strain Sporulation and Growth Conditions

The *S. griseochromogenes* wild-type and $\Delta ttnD$ and $\Delta ttnF$ mutant strains SB13013 and SB13014 were grown on MS medium (consisting of autoclaved 2% mannitol, 3% soybean flour, and 1.8% agar in tap water) at 30 °C until they were well sporulated (7 days). Spores were then harvested and stored in 20% glycerol at –80°C using previously reported standard procedures.

Plasmids and DNA Manipulation

Plasmid extraction and DNA purification were carried out using commercial kits (Qiagen, Santa Clarita, CA) and genomic DNAs isolated according to literature protocol.³⁰ The digoxigenin-11-dUTP labeling and detection kit (Roche Diagnostics Corp, Indianapolis, IN.) was used for preparation of DNA probes, and Southern hybridization was carried out as per manufacturer instructions.

Construction of $\Delta ttnD$ and $\Delta ttnF$ Mutant Strains SB13013 and SB13014

The *ttnD* and *ttnF* genes were inactivated by application of REDIRECT Technology according to the literature protocols.^{6,29} An apramycin (Apr) resistance gene *aac(3)IV/oriT* cassette was used to replace an internal region of each target gene. Mutant cosmids pBS13025 ($\Delta ttnD$) and pBS13026 ($\Delta ttnF$) for gene inactivation were constructed (Table S1, Supporting Information) and then introduced into *S. griseochromogenes* by conjugation from *E. coli* ET12567/pUZ8002 according to the literature procedure with the following modifications.^{6,29,30} Thus, *S. griseochromogenes* spores were suspended in TSB medium and heat-shocked at 45°C for 15 min, followed by incubation at 30°C for 6 hr. Germinated spores (as conjugation recipients) were mixed with *E. coli* ET12567/pUZ8002 harboring mutant cosmid (as conjugation donor) and spread onto modified ISP-4 plates freshly supplemented with 20 mM MgCl₂. After incubation at 28°C for 16 to 22 h, each plate was overlaid with 1 mL of sterilized water containing Apr at a final concentration of 10 μg/mL and nalidixic acid at a final concentration of 50 μg/mL. Incubation continued at 28°C until exconjugants appeared. The double crossover mutants found to be apramycin resistant and kanamycin sensitive were selected, named SB

13013 (*AttnD*) and SB13014 (*AttnF*), and verified by PCR and subsequently confirmed by Southern analysis (Figure S1 and S2, Supporting Information).

Complementation of the $\Delta ttnD$ Mutation in SB13013 and the $\Delta ttnF$ Mutation in SB13014

To construct expression plasmids for genetic complementation experiments, *ttnD* and *ttnF* were amplified and digested by *NsiI* and *XbaI*, and then cloned into the same sites of pBS6027⁷ to give pBS13029 (for *ttnD* expression) and pBS13030 (for *ttnF* expression). They were introduced into the corresponding mutant strains by conjugation to yield complemented strains SB13015 (i.e., SB13013/pBS13029) and SB13016 (i.e., SB13014/pBS13030), respectively (Table S3).

Fermentation of *S. griseochromogenes* wild-type and Recombinant Strains and Production of TTN and Analogues

A two-stage fermentation procedure was utilized to grow the *S. griseochromogenes* wild-type and recombinant strains SB13013, SB13014, SB13015, and SB13016 for TTN and analogue production as previously described.⁶ Thus, seed medium (50 mL in 250-mL flask) was inoculated with spores, and the flasks were incubated on a rotary shaker at 250 rpm (Innova[®] 44 Incubator Shaker Series, New Brunswick Scientific Co., Inc., Edison, NJ) and 28°C for 2 days. This seed culture (50 mL) was then transferred into the fermentation medium (500 mL in 2-L flask), and the flasks were incubated on a rotary shaker at 250 rpm and 28°C for 5 days. Both seed and production media consist of glucose 2% (separately autoclaved), soluble starch 0.5%, beef extract 0.05%, yeast extract 0.3%, soybean flour 1%, NaCl 0.1%, K₂HPO₄ 0.0025%, and distilled water and tap water (1:1), pH 7.0, and were sterilized by autoclaving at 121°C for 35 min.

Extraction and Isolation of TTN (1) and Analogues (3–7) from *S. griseochromogenes* Fermentation

The typical procedure for extraction and isolation of TTN and analogues from *S. griseochromogenes* wild-type and recombinant strain fermentation is as follows. The fermentation broth (10 L) was harvested by first bringing the broth pH to 4.0 via dropwise addition of 1 N HCl. Fermentation mixtures were then centrifuged at 3800 RPM (SLC-6000 rotor, Sorvall[®] Evolution RC, Thermo Scientific Inc., Waltham, MA) at 4°C for 20 min to pellet the mycelia. Broth supernatants were then collected and filtered to afford transparent amber colored supernatants. Supernatants were then adsorbed onto 1.8 L of XAD-16 resin twice. Resins (now bearing secondary metabolites) were then washed with 5.4 L distilled water to remove residual cells and broth components and then subjected to 3.6 L acetone to elute the absorbed compounds. Acetone was removed under vacuum to give the crude products, and these products were then dissolved into 600 mL acidic water (pH = 4.0). Acidic aqueous fractions were then extracted three times with 900 mL ethyl acetate (300 mL fresh solvent each time). The resulting organic layers were combined and dried over anhydrous sodium sulfate. Following removal of all solids, the ethyl acetate was removed under reduced pressure to afford the crude syrups containing TTN and analogues. The syrups were then subjected to column chromatography over silica gel 60 RP-18 eluted with acetonitrile and water (from 2:8 to 9:1; 300 mL each) gradient. Each 100 mL fraction was analyzed by analytical HPLC, employing a detection wavelength of 264 nm and a linear gradient running from a buffer A/buffer B composition of 70:30 to 100% buffer B over the course of 24 min and continued at 100 % buffer B for an additional 3 min, at a flow rate of 1 mL/min. Fractions containing TTN or analogues were combined and the solvents removed under reduced pressure for further purification by HPLC on analytic or semi-preparative C-18 column. Precise purification procedures for each compound are noted below. Following collection of relevant fractions from HPLC, samples were frozen in dry ice and then solvent lyophilized for 12h.

For purification of TTN (1) and TTN F-1 (3) semi-preparative HPLC was carried out on an Alltech Alltima C-18 column (250 × 10.0 mm, 5 μm), employing a linear gradient from buffer A/buffer B (70:30) to 100% buffer B over 24 min and continued at 100% buffer B for an additional 3 min, at a flow rate of 3 mL/min and monitored by UV detection at 264 nm.

For purification of TTN D-1 (4) a linear gradient from buffer A/buffer B (90:10) to 100% buffer B over 20 min and continued at 100% buffer B for an additional 3 min, at a flow rate of 3 mL/min and UV detection at 264 nm.

For purification of diastereomers 5 and 6, an effective linear gradient involved ramping from buffer A/buffer B (60:40) to buffer A/buffer B (20:80) over 16 min with continued flow at 100% buffer B for an additional 2 min, at a flow rate of 3 mL/min and UV detection at 264 nm. The first peak corresponded to compound 5, and the slightly slower moving peak corresponded to compound 6.

For purification of TTN D-4 (7) a linear gradient from buffer A/buffer B (70:30) to 100% buffer B over 16 min and continued at 100% buffer B for an additional 2 min, at a flow rate of 3 mL/min and UV detection at 264 nm.

TTN F-1 (3)

Absolute yield: 16 mg from 16 L fermentation broth of SB13014. Yellowish gum;

$[\alpha]_D^{25} = +22.9$ (c 1.0, Acetone); APCI-MS (positive mode) m/z : 637 ($[M-H_2O+H]^+$, 15), 619 ($[M-2H_2O+H]^+$, 50), 601 ($[M-3H_2O+H]^+$, 15), 281 (80), 263 (100), and 139 (65); HR-ESI-MS (negative mode) m/z : 653.3532 $[M-H]^-$ (calcd for $C_{34}H_{53}O_{12}$, 653.3543, -1.6 ppm Error); IR: 3415, 2930, 1766, 1707, 1457, 1427, 1364, 1269, 1225, 1180, 1110, 1073, 1048, 910, 824, 794, and 706 cm^{-1} ; For 1H - and ^{13}C -NMR data, see Table 1.

TTN D-1 (4)

Absolute yield: 17 mg from 40 L fermentation broth of SB 13013. Off-yellowish gum;

$[\alpha]_D^{25} = +20.0$ (c 1.0, acetone); APCI-MS (negative mode) m/z : 635 ($[M-H]^-$, 100); HR-MALDI-MS (positive mode) m/z : 659.3412 $[M+Na]^+$ (calcd for $C_{34}H_{52}O_{11}Na$, 659.3402, 1.58 ppm Error); IR: 3422, 2930, 1766, 1706, 1621, 1515, 1456, 1364, 1259, 1222, 1177, 1089, 1062, 1029, 985, 907, 852, 764, and 731 cm^{-1} ; For 1H - and ^{13}C -NMR data, see Table 1.

TTN D-2 (5)

Absolute yield: 30 mg from 40 L fermentation broth of SB13013. Off-yellowish gum;

$[\alpha]_D^{25} = +12.0$ (c 2.0, acetone); APCI-MS (negative mode) m/z : 651 ($[M-H]^-$, 100); HR-ESI-MS (negative mode) m/z : 651.3400 $[M-H]^-$ (calcd for $C_{34}H_{51}O_{12}$, 651.3375, 3.83 ppm Error); IR: 3407, 2931, 1830, 1765, 1703, 1621, 1456, 1365, 1260, 1223, 1179, 1032, 986, 957, 907, 854, and 732 cm^{-1} ; For 1H - and ^{13}C -NMR data, see Table 2.

TTN D-3 (6)

Absolute yield: 12 mg from 40 L fermentation broth of SB13013. Off-yellowish gum;

$[\alpha]_D^{25} = +21.8$ (c 1.0, acetone); APCI-MS (negative mode) m/z : 651 ($[M-H]^-$, 100); HR-ESI-MS (negative mode) m/z : 651.3399 $[M-H]^-$ (calcd for $C_{34}H_{51}O_{12}$, 651.3375, 3.68 ppm Error); IR: 3406, 29671, 1830, 1765, 1703, 1621, 1456, 1365, 1260, 1223, 1179, 1040, 985, 956, 908, 855, and 732 cm^{-1} ; For 1H - and ^{13}C -NMR data, see Table 2.

TTN D-4 (7)

Absolute yield: 4 mg from 40 L fermentation broth of SB13013. Off-yellowish gum; $[\alpha]_D^{25} = +12.0$ (c 2.0, acetone); APCI-MS (negative mode) m/z : 649 ($[M-H]^-$, 100); HR-ESI-MS (negative mode) m/z : 649.3239 $[M-H]^-$ (calcd for $C_{34}H_{49}O_{12}$, 649.3219, 3.15 ppm Error); IR: 3416, 2966, 1829, 1765, 1704, 1625, 1581, 1457, 1378, 1261, 1181, 1090, 1033, 986, 957, 908, and 732 cm^{-1} ; for 1H - and ^{13}C -NMR data, see Table 1.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the Analytical Instrumentation Center of the School of Pharmacy, UW-Madison for support in obtaining MS and NMR data. This work is supported in part by NIH grants CA106150 and CA113297. Y.L. is the recipient of the visiting scholar fellowship from Chinese Academy of Sciences.

References

1. (a) Cheng XC, Kihara T, Ying X, Uramoto M, Osada H, Kusakabe H, Wang BN, Kobayashi Y, Ko K, Yamaguchi I, Shen YC, Isono K. *J. Antibiot* 1989;42:141–144. [PubMed: 2921220] (b) Cheng XC, Kihara T, Kusakabe H, Magae J, Kobayashi Y, Fang RP, Ni ZF, Shen YC, Ko K, Yamaguchi I, Isono K. *J. Antibiot* 1987;40:907–909. [PubMed: 3610839]
2. Mitsuhashi S, Matsuura N, Ubukata M, Oikawa H, Shima H, Kikuchi K. *Biochem. Biophys. Res. Commun* 2001;287:328–331. [PubMed: 11554729]
3. Shim JH, Lee HK, Chang EJ, Chae WJ, Han JH, Han DJ, Morio T, Yang JJ, Bothwell A, Lee SK. *Proc. Natl. Acad. Sci. U.S.A* 2002;99:10617–10622. [PubMed: 12149481]
4. Bialojan C, Takai A. *Biochem. J* 1988;256:283–290. [PubMed: 2851982]
5. Lee JH, Lee JS, Kim SE, Moon BS, Kim YC, Lee SK, Lee SK, Choi KY. *Mol. Cancer Ther* 2006;5:3222–3231. [PubMed: 17172426]
6. Li W, Luo Y, Ju J, Rajski SR, Osada H, Shen B. *J. Nat. Prod* 2009;72:450–459. [PubMed: 19191560]
7. Li W, Ju J, Rajski SR, Osada H, Shen B. *J. Biol. Chem* 2008;283:28607–28617. [PubMed: 18708355]
8. Oikawa H. *Curr. Med. Chem* 2002;9:2033–2054. [PubMed: 12369869]
9. Nishiyama U, Ubukata M, Magae J, Kataoka T, Erdoedi F, Hartshorne DJ, Isono K, Nagai K, Osada H. *Biosci. Biotech. Biochem* 1996;60:103–107.
10. Sheppeck JE II, Liu WM, Chamberlin AR. *J. Org. Chem* 1997;62:387–398. [PubMed: 11671414]
11. Takai A, Tsuboi K, Koyasu M, Isobe M. *Biochem. J* 2000;350:81–88. [PubMed: 10926829]
12. Kelker MS, Page R, Peti W. *J. Mol. Biol* 2009;385(1):11–21. [PubMed: 18992256]
13. Cheng XC, Ubukata M, Isono K. *J. Antibiot* 1990;43:890–896. [PubMed: 2387780]
14. Cheng XC, Ubukata M, Isono K. *J. Antibiot* 1990;43:809–819. [PubMed: 2387775]
15. Keatinge-Clay AT. *Chem. Biol* 2007;14:898–908. [PubMed: 17719489]
16. (a) Dale JAH, Mosher S. *J. Am. Chem. Soc* 1973;95:512–519. (b) Ohtani I, Kusumi T, Kashman Y, Kakisawa H. *J. Am. Chem. Soc* 1991;113:4092–4096.
17. Uhrin D, Batta G, Hruby VJ, Barlow PN, Kövér KE. *J. Magn. Reson* 1998;130:155. [PubMed: 9515088]
18. Williamson RT, Márquez BL, Gerwick WH, Kövér KE. *Magn. Reson. Chem* 2000;38:265.
19. Ju J, Li W, Yuan Q, Peters NR, Hoffmann FM, Rajski SR, Osada H, Shen B. *Org. Lett* 2009;11:1639–1642. [PubMed: 19281218]
20. Chang ZX, Sitachitta N, Rossi JV, Roberts MA, Flatt PM, Jia JY, Sherman DH, Gerwick WH. *J. Nat. Prod* 2004;67:1356–1367. [PubMed: 15332855]
21. Gu L, Wang B, Kulkarni A, Gehret JJ, Lloyd KR, Gerwick L, Gerwick WH, Wipf P, Hakansson K, Smith JL, Sherman DH. *J. Am. Chem. Soc* 2009;131:16033–16035. [PubMed: 19835378]

22. Zhang J, Van Lanen SG, Ju J, Liu W, Dorrestein PC, Li W, Kelleher NL, Shen B. *Proc. Natl. Acad. Sci. U.S. A* 2008;105:1460–1465. [PubMed: 18223152]
23. Liu W, Sheppeck JE II, Colby DA, Huang H-B, Nairn AC, Chamberlin AR. *Bioorg. Med. Chem. Lett* 2003;13:1597–1600. [PubMed: 12699763]
24. Oikawa H, Yoneta Y, Ueno T, Oikawa M, Wakayama T, Ichihara A, Kawamura T, Matsuzawa S-I, Kikuchi K. *Tennen Yuki Kagobutsu Toronkai Koen Yoshishu* 1997;39:433–438.
25. Isobe M. *Yuki, Gosei Kagaku Kyokaishi* 1997;55:60–71.
26. Oikawa H, Oikawa M, Ichihara A, Ubukata M, Isono K. *Biosci. Biotech. Biochem* 1994;58:1933–1935.
27. Sambrook, JE.; Fritsch, EF.; Maniatis, T. *Molecular cloning a Laboratory Manual*. 3rd Ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2000.
28. Paget MS, Chamberlin L, Atrih A, Foster SJ, Buttner MJ. *J. Bacteriol* 1999;181:204–211. [PubMed: 9864331]
29. Gust B, Challis GL, Fowler K, Kieser T, Chater KF. *Proc. Natl. Acad. Sci. U.S.A* 2003;100:1541–1546. [PubMed: 12563033]
30. Kieser, T.; Bibb, MJ.; Buttner, MJ.; Chater, KF.; Hopwood, DA. *Practical Streptomyces Genetics*. Norwich UK: John Innes Foundation; 2000.
31. Liu W, Shen B. *Antimicrob. Agents Chemother* 2000;44:382–392. [PubMed: 10639366]

Tautomycetin (TTN, **1**) Tautomycin (TTM, **2**)

Figure 1.
Structures of tautomycetin (TTN, **1**) and tautomycin (TTM, **2**).

Figure 2.

TTN biosynthetic intermediates and shunt metabolites accumulated in the $\Delta ttnF$ and $\Delta ttnD$ mutant strains SB13013 and SB13014. (A) HPLC traces of metabolite profiles from *S. griseochromogenes* wild-type and mutant strains: (I) *S. griseochromogenes* wild-type. (II) SB13014, ($\Delta ttnF$ mutant); (III) SB13016 ($\Delta ttnF$ complemented); (IV) SB13013 ($\Delta ttnD$ mutant); (V) SB13015 ($\Delta ttnD$ complemented). Numbers above each peak correspond to TTN (**1**), TTN F-1 (**3**), TTN D-1 (**4**), TTN D-2 (**5**), TTN D-3 (**6**), and TTN D-4 (**7**). (B) Structures of **3** from the $\Delta ttnF$ mutant strain SB13013 and **4–7** from the $\Delta ttnD$ mutant strain SB13014 as deduced on basis of UV-vis, NMR, MS, and IR data.

Figure 3.

(A) Key ^1H - ^1H COSY and HMBC correlations observed and applied to structure determination for TTN analogs **3**–**7**. (B) Determination of the *S*-configuration at C5 of **5** on the basis of HETLOC, gHSQMBC, and gDQCOSY analyses.

Figure 4.

Proposed biosynthesis of **1** predicated on a linear biosynthetic logic leading to intermediate **3** and subsequent processing by tailoring enzymes TtnD and TtnF. Tailoring steps involving TtnF, TtnI and TtnD and their ordering are assigned on the basis of metabolites **3–7** accumulated by $\Delta ttnD$ and $\Delta ttnF$ mutant strain SB13013 and SB13014s. We envision TtnI as a C5 oxidase based on its similarity to cytochrome P450 hydroxylases. In proceeding from **3**, path a invokes the sequential actions of TtnF, TtnI, and TtnD with **5** and **6** most likely derived by adventitious reduction of **7**. Path b invokes coordinated activity by both TtnD and TtnF to produce a diene intermediate, which is subsequent oxidized at C5 by TtnI to afford **1**. Molecular fragments not shown are identical to those of their putative precursor **3**. The current studies disprove the intermediacy of 1''-hydroxy-5-keto-acid in **1** biosynthesis proposed previously.⁶

Table 1

Summary of ^1H and ^{13}C NMR data for compounds **3**, **4**, and **7** in CDCl_3^{ab}

Position	3			4			7		
	δ_{H}^c (J in Hz)	δ_{C}^d	δ_{H}^e (J in Hz)	δ_{C}^d	δ_{H}^e (J in Hz)	δ_{C}^d	δ_{H}^e (J in Hz)	δ_{C}^d	
1	1.06 (3H, t, $J=7.5$)	13.8	1.02 (3H, t, $J=7.6$)	13.8	1.10 (3H, t, $J=7.6$)	13.8	1.10 (3H, t, $J=7.6$)	13.8	
2	2.71 (2H, q, $J=7.5$)	21.0	2.67 (2H, q, $J=7.2$)	20.0	2.71 (2H, q, $J=7.6$)	21.2	2.71 (2H, q, $J=7.6$)	21.2	
3		141.4		139.2		153.0		153.0	
4	5.48 (1H, t, $J=7.0$)	127.1	5.88 (1H, t, $J=7.2$)	143.8	6.34 (1H, s)	132.0		132.0	
5	2.10 (2H, m)	24.7	2.20 (2H, m)	26.4		201.5		201.5	
6	1.19 (1H, m)	36.5	1.21 (1H, m)	37.2	2.28 (1H, dd, $J=15.6$, 8.0)	53.0		53.0	
	1.41 (1H, m)		1.33 (1H, m)						
7	1.58 (1H, m)	28.9	1.47 (1H, m)			27.4		27.4	
7-CH ₃	0.88 (3H, d, $J=6.5$)	20.1	0.83 (3H, d, $J=6.4$)	19.5	0.89 (3H, d, $J=6.4$)	20.2		20.2	
8	1.20 (2H, m)	45.3	1.09 (2H, m)	45.0	1.15 (2H, m)	45.0		45.0	
9	1.54 (1H, m)	29.6	1.52 (1H, m)	30.2	1.50 (1H, m)	30.0		30.0	
9-CH ₃	0.89 (3H, d, $J=6.5$)	20.3	0.86 (3H, d, $J=6.8$)	19.6	0.86 (3H, d, $J=6.4$)	19.5		19.5	
10	1.44 (2H, m)	31.3	1.30 (2H, m)	33.1	1.30 (2H, m)	31.7		31.7	
11	1.58 (2H, m)	31.2	1.52 (2H, m)	32.0	1.40 (2H, m)	32.4		32.4	
12	3.82 (1H, m)	73.6	3.73 (1H, m)	74.0	3.73 (1H, m)	73.7		73.7	
13	2.70 (1H, dq, $J=8.5$, 7.0)	53.0	2.65 (1H, dq, $J=8.0$, 7.2)	53.0	2.65 (1H, dq, $J=7.8$, 7.6)	53.0		53.0	
13-CH ₃	1.12 (3H, d, $J=7.0$)	14.3	1.08 (3H, d, $J=7.2$)	13.6	1.08 (3H, d, $J=7.2$)	13.8		13.8	
14		215.9		215.9		215.9		215.9	
15	2.48 (1H, dd, $J=16.5$, 2.5)	46.3	2.45 (1H, dd, $J=16.8$, 2.8)	46.6	2.45 (2H, m)	46.5		46.5	
	2.84 (1H, dd, $J=16.5$, 2.5)		2.80 (1H, dd, $J=16.8$, 2.8)						
16	4.39 (1H, dt, $J=10.0$, 2.5)	66.7	4.33 (1H, dt, $J=10.0$, 2.0)	66.8	4.33 (1H, dt, $J=9.6$, 2.4)	66.9		66.9	
17	1.74 (1H, m)	43.1	1.70 (1H, m)	43.0	1.70 (1H, m)	43.0		43.0	
17-CH ₃	0.98 (3H, d, $J=6.5$)	10.3	0.94 (3H, d, $J=7.2$)	10.5	0.94 (3H, d, $J=7.2$)	10.5		10.5	
18	5.05 (1H, dq, $J=9.0$)	73.7	5.01 (1H, dq, $J=8.0$)	73.7	5.02 (1H, dq, $J=7.2$)	73.8		73.8	

	3	4	7
	6.5)	6.4)	6.4)
18-CH ₃	1.34 (3H, d, <i>J</i> =6.5)	18.6 1.29 (3H, d, <i>J</i> =6.4)	18.6 1.30 (3H, d, <i>J</i> =6.4)
1'		170.3	170.3
2'	2.93 (1H, dd, <i>J</i> =16.0, 2.5)	40.8 2.88 (1H, dd, <i>J</i> =16.0, 8.0)	40.9 2.88 (1H, dd, <i>J</i> =16.0, 8.0)
	2.84 (1H, dd, <i>J</i> =16.0, 4.0)	2.80 (1H, dd, <i>J</i> =16.0, 4.0)	2.80 (1H, dd, <i>J</i> =16.0, 4.0)
3'	5.24 (1H, ddd, <i>J</i> =9.0, 3.5, 1.0)	64.0 5.20 (1H, ddd, <i>J</i> =8.0, 4.0, 1.2)	64.1 5.20 (1H, ddd, <i>J</i> =8.8, 3.6, 1.2)
4'		142.4	142.3
5'		143.3	143.3
5'-CH ₃	2.31 (3H, d, <i>J</i> =1.0)	10.4 2.27 (3H, d, <i>J</i> =1.2)	10.3 2.27 (3H, d, <i>J</i> =1.2)
6'		165.9	165.9
7'		165.1	165.0
1''	4.49 (1H, dd, <i>J</i> =7.5, 4.5)	71.8 7.28 (1H, d, <i>J</i> =15.2)	151.0 7.23 (1H, d, <i>J</i> =16.0)
2''	2.60 (2H, m)	40.5 5.78 (1H, d, <i>J</i> =15.2)	114.3 6.26 (1H, d, <i>J</i> =16.0)
3''		175.4	172.3
			170.4

^a Chemical shifts are reported in ppm, coupling constants are in Hertz.

^b all signals are determined by ¹H-¹H COSY, HSQC, and HMBC correlations,

^c ¹H-NMR: 500 MHz,

^d ¹³C-NMR: 100 MHz,

^e ¹H-NMR: 400 MHz.

Table 2Summary of ^1H and ^{13}C NMR data for compounds **5** and **6** in CDCl_3^{ab}

position	5		6	
	δ_{H}^c (J in Hz)	δ_{C}^d	δ_{H}^c (J in Hz)	δ_{C}^d
1	1.07 (3H, t, $J=7.2$)	13.8	1.05 (3H, t, $J=7.6$)	13.8
2	2.32 (2H, q, $J=7.2$)	20.4	2.30 (2H, q, $J=7.6$)	20.4
3		140.2		140.2
4	5.77 (1H, d, $J=8.8$)	143.3	5.82 (1H, d, $J=8.8$)	143.6
5	4.58 (1H, q like, $J=7.6$)	66.6	4.56 (1H, dt, $J=9.2, 3.2$)	66.5
6	1.18, 1.47 (each 1H, m)	45.0	1.10, 1.67 (each 1H, m)	45.6
7	1.57 (1H, m)	26.7	1.75 (1H, m)	26.5
7-CH ₃	0.89 (3H, d, $J=6.4$)	21.0	0.93 (3H, d, $J=6.4$)	20.3
8	1.08, 1.17 (each 1H, m)	45.3	1.05, 1.16 (each 1H, m)	44.6
9	1.40 (1H, m)	32.1	1.55 (1H, m)	31.4
9-CH ₃	0.84 (3H, d, $J=6.4$)	19.7	0.84 (3H, d, $J=6.4$)	20.1
10	1.28 (2H, m)	29.8	1.28 (2H, m)	29.2
11	1.38 (2H, m)	31.7	1.38 (2H, m)	31.5
12	3.75 (1H, m)	73.6	3.78 (1H, dt, $J=8.8, 2.4$)	73.2
13	2.64 (1H, dq, $J=7.6, 7.2$)	53.1	2.65 (1H, dq, $J=7.6, 7.2$)	52.9
13-CH ₃	1.08 (3H, d, $J=7.2$)	14.2	1.07 (3H, d, $J=7.2$)	14.0
14		215.8		215.8
15	2.79 (1H, dd, $J=16.4, 6.0$)	46.4	2.79 (1H, dd, $J=16.8, 6.0$)	46.7
	2.44 (1H, dd, $J=16.4, 2.4$)		2.46 (1H, dd, $J=16.8, 2.4$)	
16	4.35 (1H, dt, $J=9.6, 2.4$)	66.7	4.35 (1H, dt, $J=10.0, 2.4$)	66.7
17	1.70 (1H, m)	43.1	1.70 (1H, m)	43.1
17-CH ₃	0.94 (3H, d, $J=6.8$)	10.4	0.93 (3H, d, $J=6.8$)	10.4
18	4.99 (1H, dq, $J=7.2, 6.0$)	73.7	4.98 (1H, dq, $J=7.2, 6.0$)	73.7
18-CH ₃	1.29 (3H, d, $J=6.4$)	18.6	1.28 (3H, d, $J=6.4$)	18.6
1'		170.3		170.2
2'	2.88 (1H, dd, $J=16.4, 4.4$)	40.9	2.88 (1H, dd, $J=16.0, 4.0$)	40.9
	2.80 (1H, dd, $J=16.4, 9.2$)		2.80 (1H, dd, $J=16.0, 8.8$)	
3'	5.19 (1H, ddd, $J=7.6, 4.0, 1.2$)	63.9	5.19 (1H, ddd, $J=7.2, 4.0, 1.2$)	63.9
4'		142.4		142.4
5'		143.1		143.2
5'-CH ₃	2.26 (3H, d, $J=0.8$)	10.3	2.26 (3H, d, $J=1.2$)	10.3
6'		166.0		166.0
7'		165.1		165.1
1''	7.25 (1H, d, $J=16.0$)	149.8	7.24 (1H, d, $J=16.0$)	149.8
2''	5.90 (1H, d, $J=16.0$)	117.0	5.89 (1H, d, $J=16.0$)	116.9
3''		170.9		171.2

^aChemical shifts are reported in ppm, coupling constants are in Hertz,

^b all signals are determined by ¹H-¹H COSY, HSQC, and HMBC correlations,

^c¹H-NMR: 400 MHz,

^d¹³C-NMR: 100 MHz.

Table 3

Summary of in vitro inhibition data (IC_{50} in μM) for TTN and analogs against PP-1 and PP-2.

Compound	PP-1	PP-2A	PP-1/PP-2A
TTN (1)	$15 \pm 0.8 \times 10^{-3}$	0.40 ± 0.04	1:27
TTN F-1 (3)	0.17 ± 0.01	0.64 ± 0.08	1:3.8
TTN D-1 (4)	0.13 ± 0.02	0.52 ± 0.05	1:4
TTN D-2 (5)	9.8 ± 0.1	44 ± 0.1	1:4.5
TTN D-3 (6)	0.21 ± 0.03	0.80 ± 0.06	1:3.8
TTN D-4 (7)	0.28 ± 0.02	0.92 ± 0.04	1:3.3

Table 4

Summary of in vitro cytotoxicity data (IC₅₀ in μ M) for TTN and analogs against selected human cancer cell lines.

Compound	Du145	MCF7	HCT-115
TTN (1)	5.2 $\pm$ 0.4	8.9 $\pm$ 0.9	6.8 $\pm$ 0.6
TTN F-1 (3)	nd ^a	nd	nd
TTN D-1 (4)	nd	nd	nd
TTN D-2 (5)	nd	nd	nd
TTN D-3 (6)	14 $\pm$ 3	11 $\pm$ 3	16 $\pm$ 3
TTN D-4 (7)	13 $\pm$ 4	17 $\pm$ 3	18 $\pm$ 3

^a nd, no significant activity detected.